Literature DB >> 29299466

Semaglutide seems to be more effective the other GLP-1Ras.

Jens Juul Holst1, Sten Madsbad2.   

Abstract

Year:  2017        PMID： 29299466      PMCID： PMC5750268          DOI： 10.21037/atm.2017.11.10

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  32 in total

1.  Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.

Authors:  Vanita R Aroda; Stephen C Bain; Bertrand Cariou; Milivoj Piletič; Ludger Rose; Mads Axelsen; Everton Rowe; J Hans DeVries
Journal:  Lancet Diabetes Endocrinol       Date:  2017-03-23       Impact factor: 32.069

2.  Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Rury R Holman; M Angelyn Bethel; Robert J Mentz; Vivian P Thompson; Yuliya Lokhnygina; John B Buse; Juliana C Chan; Jasmine Choi; Stephanie M Gustavson; Nayyar Iqbal; Aldo P Maggioni; Steven P Marso; Peter Öhman; Neha J Pagidipati; Neil Poulter; Ambady Ramachandran; Bernard Zinman; Adrian F Hernandez
Journal:  N Engl J Med       Date:  2017-09-14       Impact factor: 91.245

3.  Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.

Authors:  Dilan Athauda; Kate Maclagan; Simon S Skene; Martha Bajwa-Joseph; Dawn Letchford; Kashfia Chowdhury; Steve Hibbert; Natalia Budnik; Luca Zampedri; John Dickson; Yazhou Li; Iciar Aviles-Olmos; Thomas T Warner; Patricia Limousin; Andrew J Lees; Nigel H Greig; Susan Tebbs; Thomas Foltynie
Journal:  Lancet       Date:  2017-08-03       Impact factor: 79.321

4.  Liraglutide: short-lived effect on gastric emptying -- long lasting effects on body weight.

Authors:  J Jelsing; N Vrang; G Hansen; K Raun; M Tang-Christensen; L Bjerre Knudsen
Journal:  Diabetes Obes Metab       Date:  2012-02-08       Impact factor: 6.577

Review 5.  Regulation of intestinal chylomicron production by glucagon-like peptides.

Authors:  Joanne Hsieh; Khosrow Adeli
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2012-12

6.  Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.

Authors:  Juris J Meier; Baptist Gallwitz; Stefan Salmen; Oliver Goetze; Jens J Holst; Wolfgang E Schmidt; Michael A Nauck
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

7.  Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.

Authors:  K Hermansen; T A Bækdal; M Düring; A Pietraszek; L S Mortensen; H Jørgensen; A Flint
Journal:  Diabetes Obes Metab       Date:  2013-06-11       Impact factor: 6.577

8.  Glucagon-like peptide-1 prevents beta cell glucolipotoxicity.

Authors:  J Buteau; W El-Assaad; C J Rhodes; L Rosenberg; E Joly; M Prentki
Journal:  Diabetologia       Date:  2004-04-17       Impact factor: 10.122

9.  Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.

Authors:  Jesper Lau; Paw Bloch; Lauge Schäffer; Ingrid Pettersson; Jane Spetzler; Jacob Kofoed; Kjeld Madsen; Lotte Bjerre Knudsen; James McGuire; Dorte Bjerre Steensgaard; Holger Martin Strauss; Dorte X Gram; Sanne Møller Knudsen; Flemming Seier Nielsen; Peter Thygesen; Steffen Reedtz-Runge; Thomas Kruse
Journal:  J Med Chem       Date:  2015-09-11       Impact factor: 7.446

10.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse
Journal:  N Engl J Med       Date:  2016-06-13       Impact factor: 176.079
View more
  10 in total

1.  Erratum to semaglutide seems to be more effective the other GLP-1Ras.

Authors:  Jens Juul Holst; Sten Madsbad
Journal:  Ann Transl Med       Date:  2018-02

Review 2.  Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review.

Authors:  Manoj K Mahapatra; Muthukumar Karuppasamy; Biswa M Sahoo
Journal:  Pharm Res       Date:  2022-06-01       Impact factor: 4.580

Review 3.  Battle of GLP-1 delivery technologies.

Authors:  Minzhi Yu; Mason M Benjamin; Santhanakrishnan Srinivasan; Emily E Morin; Ekaterina I Shishatskaya; Steven P Schwendeman; Anna Schwendeman
Journal:  Adv Drug Deliv Rev       Date:  2018-07-21       Impact factor: 15.470

4.  Evaluation of Patient-Reported Satisfaction and Clinical Efficacy of Once-Weekly Semaglutide in Patients with Type 2 Diabetes: An Ambispective Study.

Authors:  Ayman A Al Hayek; Mohamed A Al Dawish
Journal:  Adv Ther       Date:  2022-02-04       Impact factor: 3.845

Review 5.  Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing.

Authors:  Stephen C Cunnane; Mark J Millan; Eugenia Trushina; Cecilie Morland; Alessandro Prigione; Gemma Casadesus; Zane B Andrews; M Flint Beal; Linda H Bergersen; Roberta D Brinton; Suzanne de la Monte; Anne Eckert; Jenni Harvey; Ross Jeggo; Jack H Jhamandas; Oliver Kann; Clothide Mannoury la Cour; William F Martin; Gilles Mithieux; Paula I Moreira; Michael P Murphy; Klaus-Armin Nave; Tal Nuriel; Stéphane H R Oliet; Frédéric Saudou; Mark P Mattson; Russell H Swerdlow
Journal:  Nat Rev Drug Discov       Date:  2020-07-24       Impact factor: 84.694

Review 6.  Systematic Review of Efficacy and Safety of Newer Antidiabetic Drugs Approved from 2013 to 2017 in Controlling HbA1c in Diabetes Patients.

Authors:  Sivanandy Palanisamy; Emily Lau Hie Yien; Ling Wen Shi; Low Yi Si; See Hui Qi; Laura Soon Cheau Ling; Teng Wai Lun; Yap Nee Chen
Journal:  Pharmacy (Basel)       Date:  2018-06-27

7.  Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle?

Authors:  Maria Kalogirou; Emmanouil Sinakos
Journal:  World J Hepatol       Date:  2018-11-27

8.  Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria.

Authors:  Chiara Di Loreto; Viviana Minarelli; Giovanni Nasini; Roberto Norgiolini; Paola Del Sindaco
Journal:  Diabetes Ther       Date:  2022-03-01       Impact factor: 3.595

Review 9.  Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review.

Authors:  Nasser M Alorfi; Alanood S Algarni
Journal:  Clin Pharmacol       Date:  2022-08-03

10.  Albumin-binding tag derived Exendin-4 analogue for treating hyperglycemia and diabetic complications.

Authors:  Shujuan Xu; Fang Wang; Hui Li; Ya Wang; Dongzhong Fang
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.